BioLab Holdings Partners with Terraplasma Medical to Innovate Wound Care

BioLab Holdings, Inc., a medical manufacturing company based in Phoenix, is set to revolutionize the wound care industry with its latest strategic investment in cold atmospheric plasma (CAP) technology. In collaboration with German company Terraplasma Medical GmbH, BioLab aims to bring an innovative solution to the U.S. healthcare market.

Partnership Highlights

On October 24, 2025, BioLab proudly announced its investment and commercialization partnership with Terraplasma Medical, a pioneer in developing plasmapax®, a portable cold plasma device designed for antimicrobial treatment in various medical fields like wound care and dermatology. This partnership underscores BioLab's commitment to enhancing medical technology that offers safer and more efficient care options.

The partnership will grant Terraplasma Medical access to U.S. healthcare markets, allowing them to leverage BioLab’s extensive distribution network. Dr. Christian Zschocke, the majority shareholder at Terraplasma, emphasized that BioLab's entrepreneurial vision aligned with their goals, making it an appealing alliance. Jens Kirsch, the company's Managing Director, echoed this sentiment, stating that BioLab's diverse product portfolio aligns with their growth strategy.

The Technology Behind CAP

Terraplasma Medical’s innovative battery-powered device generates cold plasma using atmospheric air, eliminating a wide array of pathogens in a non-invasive and chemical-free manner. Each device can support over 120 treatments per charge and employs disposable sterile spacers for convenience and safety. This technology has delivered over 100,000 successful treatments globally and is CE-marked, validating its efficacy through years of research.

BioLab President Jaime Leija commented on the significance of this collaboration, highlighting that it represents a substantial advancement in the paradigm of infection control. By integrating Terraplasma's cold plasma technology into their offerings, BioLab aims to deliver improved care solutions for clinicians and patients.

Regulatory Approvals and Future Goals

The partnership is poised to expand the footprint of Terraplasma's technology in the U.S. as the medical device pursues FDA 510(k) clearance. BioLab’s investment will not only aid in navigating this regulatory landscape but also enhance the commercialization efforts, ensuring the product reaches healthcare providers effectively.

Experts from BioLab, including Chief Science Officer Dr. Carlos Encinas, view cold plasma technology as a transformative frontier in antimicrobial treatment. The handheld format of Terraplasma’s device combines extensive scientific research with practical usability, aligning perfectly with BioLab’s mission to provide innovative healthcare solutions.

Comprehensive Care Solutions

The collaboration between BioLab and Terraplasma underscores an overarching goal: delivering comprehensive care solutions that benefit patients, providers, and payers alike. With insights driven by distributor and provider feedback, the alliance is expected to pave the way for next-generation medical treatments in wound care.

About BioLab Holdings, Inc.

BioLab Holdings, Inc. specializes in the realm of wound healing, offering a range of products designed to enhance recovery and improve patient outcomes. Their offerings include advanced wound care solutions using human tissue allografts, aiming to manufacture safe and reliable healthcare products.

About Terraplasma Medical GmbH

Based in Germany, Terraplasma Medical is pioneering the application of cold atmospheric plasma in medical fields like dermatology and podiatry. Their innovative devices not only facilitate wound healing but also offer potent antimicrobial action, tapping into strong scientific validation and regulatory approvals to set new standards in advanced plasma-based therapies worldwide.